Olivier Deas, our Head of R&D, will be delighted to meet-up with you there and explain how our specifically well characterized Breast Cancer panel has been detrimental to all PARP/DDRi research as of now. If you’re involved in PARP/DDR inhibitors’ development, you have to talk with us; we’ll share our experience and expertise with real pleasure !

XenTech proudly delivers reliable and actionnable results you can build upon !